UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$950M |
| 2 |
Linde
LIN
|
+$886M |
| 3 |
Amgen
AMGN
|
+$812M |
| 4 |
Pinduoduo
PDD
|
+$400M |
| 5 |
Advanced Micro Devices
AMD
|
+$240M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ametek
AME
|
+$475M |
| 2 |
Microsoft
MSFT
|
+$266M |
| 3 |
Amazon
AMZN
|
+$221M |
| 4 |
VMW
VMware, Inc
VMW
|
+$197M |
| 5 |
Canadian Pacific Kansas City
CP
|
+$140M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.09% |
| 2 | Healthcare | 14.47% |
| 3 | Financials | 11.11% |
| 4 | Consumer Discretionary | 10.49% |
| 5 | Industrials | 7.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALX
2501
Alexander's
ALX
$1.41B
| $204K | ﹤0.01% |
+1,053
| New | +$228K |
|
2502
SmartRent
SMRT
$272M
| $203K | ﹤0.01% |
79,431
-23,639
| -23% | -$63.4K |
|
2503
Fate Therapeutics
FATE
$326M
| $202K | ﹤0.01% |
35,408
-42,743
| -55% | -$258K |
|
2504
Forestar Group
FOR
$1.51B
| $201K | ﹤0.01% |
+12,919
| New | +$194K |
|
2505
Blue Bird Corp
BLBD
$2.18B
| $201K | ﹤0.01% |
+9,828
| New | +$175K |
|
|
FLIC
2506
DELISTED
First of Long Island Corp
FLIC
| $198K | ﹤0.01% |
14,662
+3,375
| +30% | +$56.6K |
|
2507
Purple Innovation
PRPL
$41.7M
| $196K | ﹤0.01% |
2,970
+555
| +23% | +$61.9K |
|
2508
NextDecade
NEXT
$1.78B
| $195K | ﹤0.01% |
39,200
| – | – |
|
2509
Douglas Elliman
DOUG
$162M
| $194K | ﹤0.01% |
65,423
| – | – |
|
2510
Oil States International
OIS
$491M
| $191K | ﹤0.01% |
+22,900
| New | +$194K |
|
2511
Adicet Bio
ACET
$74.7M
| $186K | ﹤0.01% |
+2,017
| New | +$253K |
|
2512
Inogen
INGN
$164M
| $185K | ﹤0.01% |
14,798
| – | – |
|
2513
Old Second Bancorp
OSBC
$1.29B
| $184K | ﹤0.01% |
13,076
-5,406
| -29% | -$86.2K |
|
2514
Hagerty
HGTY
$1.39B
| $182K | ﹤0.01% |
20,855
| – | – |
|
2515
Farmers National Banc Corp
FMNB
$930M
| $181K | ﹤0.01% |
+14,300
| New | +$198K |
|
2516
Seer Inc
SEER
$120M
| $181K | ﹤0.01% |
46,818
| – | – |
|
|
CANO
2517
DELISTED
Cano Health, Inc.
CANO
| $180K | ﹤0.01% |
1,977
| – | – |
|
2518
TaskUs
TASK
$669M
| $178K | ﹤0.01% |
12,351
-5,182
| -30% | -$90.2K |
|
|
ESPR
2519
DELISTED
Esperion Therapeutics
ESPR
| $177K | ﹤0.01% |
111,482
+39,787
| +55% | +$205K |
|
2520
4D Molecular Therapeutics
FDMT
$562M
| $174K | ﹤0.01% |
+10,149
| New | +$197K |
|
2521
Interface
TILE
$2.22B
| $174K | ﹤0.01% |
21,404
-30,815
| -59% | -$303K |
|
2522
Tiptree Inc
TIPT
$675M
| $173K | ﹤0.01% |
+11,900
| New | +$181K |
|
2523
EverQuote
EVER
$906M
| $172K | ﹤0.01% |
+12,356
| New | +$184K |
|
2524
Caribou Biosciences
CRBU
$164M
| $170K | ﹤0.01% |
32,062
-29,300
| -48% | -$182K |
|
2525
Latham Group
SWIM
$880M
| $167K | ﹤0.01% |
58,540
| – | – |
|
Similar funds
UBS AM's Q1 2023 Portfolio in Review
As of Q1 2023, UBS AM held 2,762 positions worth $206B, up 8.3% from $191B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
UBS AM's Q1 2023 filing shows 231 new, 1,328 increased, 856 reduced and 85 closed positions. Its largest new stake was Amgen: 3,308,425 shares worth $800M. The largest sale was Ametek, an estimated $475M.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 25% a quarter earlier, followed by Healthcare and Financials.
- UBS AM's largest Q1 2023 buy was Amgen: 3,308,425 shares worth $800M.
- UBS AM added most to Abbott in Q1 2023, an estimated $950M increase.
- UBS AM's biggest Q1 2023 reduction was Ametek, cutting an estimated $475M.
- UBS AM fully exited SVB Financial Group in Q1 2023, selling an estimated $77.3M.
- UBS AM's ten largest holdings make up 22% of its $206B portfolio in Q1 2023.
- UBS AM opened 231 new positions and closed 85 in Q1 2023.
- UBS AM's portfolio value rose 8.3% quarter-over-quarter to $206B.
Based on UBS AM's 13F filing for Q1 2023, filed 15 May 2023.